2 documents found, page 1 of 1
REALMS study: real-world effectiveness and safety of fingolimod in patients wit...
Batista, S; Nunes, C; Cerqueira, J; Silva, A; Sá, J; Ferreira, J; Mendonça, M; Pinheiro, J; Salgado, V, et al.Background: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting multiple sclerosis (RRMS). Objectives: To assess the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice in Portugal. Methods: Retrospective, multicentre, non-interventional study, reporting 3 years follow-up of data collected from October 2015 to July 2...
A multicenter, non-interventional study to evaluate the disease activity in Mul...
Ladeira, F; Braz, L; Salgado, P; Vaz, S; Leitão, L; Félix, C; Salgado, V, et al.Abstract OBJECTIVES: Natalizumab (NTZ) is very effective for treatment of relapsing-remitting multiple sclerosis (RRMS), its use is mainly limited by safety issues. Discontinuation of NTZ is associated with recurrence of disease activity (reactivation and rebound). The best strategy for subsequent therapy and the predictive factors for recurrence in such patients are areas of active research. We aimed to evalua...